Drug Trial Radar · NCT05441267
A Study of Cardiovascular Events iN Diabetes Plus
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21,296
Actual
Start
Mar 13, 2023
Primary completion
Aug 17, 2028
Study completion Aug 17, 2048
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novo Nordisk A/S
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Semaglutide Oral TabletDrug
Oral semaglutide 14mg daily (option to reduce to 7mg daily)
Placebo oral tabletDrug
Placebo oral semaglutide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+)Time frame: Scheduled treatment period (anticipated median follow-up period of 5-years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Service Unit and Epidemiological Studies Unit
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.